| Index | S&P 500 | P/E | 51.19 | EPS (ttm) | 1.74 | Insider Own | 0.26% | Shs Outstand | 576.40M | Perf Week | 2.85% |
| Market Cap | 51.34B | Forward P/E | 26.30 | EPS next Y | 3.39 | Insider Trans | -9.20% | Shs Float | 569.39M | Perf Month | 3.90% |
| Enterprise Value | 47.77B | PEG | 4.48 | EPS next Q | - | Inst Own | 86.87% | Short Float | 1.68% | Perf Quarter | 7.26% |
| Income | 1.00B | P/S | 7.88 | EPS this Y | 15.53% | Inst Trans | 0.00% | Short Ratio | 2.46 | Perf Half Y | 5.85% |
| Sales | 6.51B | P/B | 4.79 | EPS next Y | 12.93% | ROA | 7.25% | Short Interest | 9.54M | Perf YTD | 4.48% |
| Book/sh | 18.61 | P/C | 12.07 | EPS next 5Y | 11.43% | ROE | 9.69% | 52W High | 96.29 -7.50% | Perf Year | 15.92% |
| Cash/sh | 7.38 | P/FCF | 35.81 | EPS past 3/5Y | -9.14% 7.08% | ROIC | 10.20% | 52W Low | 74.66 19.30% | Perf 3Y | 27.77% |
| Dividend Est. | - | EV/EBITDA | 30.18 | Sales past 3/5Y | 4.08% 6.71% | Gross Margin | 77.98% | Volatility | 1.95% 2.36% | Perf 5Y | -20.59% |
| Dividend TTM | - | EV/Sales | 7.33 | EPS Y/Y TTM | -75.04% | Oper. Margin | 28.09% | ATR (14) | 2.04 | Perf 10Y | 125.19% |
| Dividend Ex-Date | - | Quick Ratio | 3.77 | Sales Y/Y TTM | 19.72% | Profit Margin | 15.43% | RSI (14) | 56.00 | Recom | 2.33 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.52 | EPS Q/Q | 16.42% | SMA20 | 2.59% | Beta | 0.83 | Target Price | 102.44 |
| Payout | 0.00% | Debt/Eq | 0.07 | Sales Q/Q | 13.64% | SMA50 | 1.15% | Rel Volume | 0.92 | Prev Close | 90.09 |
| Employees | 16,000 | LT Debt/Eq | 0.07 | Earnings | Nov 04 | SMA200 | 4.51% | Avg Volume | 3.39M | Price | 89.07 |
| IPO Date | Mar 27, 2000 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 4.97% 2.40% | Net Debt/EBITDA | -1.39 | Volume | 3,100,986 | Change | -1.13% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-28-26 | Reiterated | UBS | Neutral | $94 → $110 |
| Jul-24-26 | Upgrade | Leerink Partners | Market Perform → Outperform | $138 → $101 |
| Jul-24-26 | Reiterated | Piper Sandler | Overweight | $100 → $101 |
| Jul-16-26 | Reiterated | Truist Securities | Hold | $90 → $95 |
| Jul-13-26 | Reiterated | RBC Capital | Outperform | $100 → $110 |
| Jul-06-26 | Reiterated | Evercore ISI Group | Outperform | $93 → $100 |
| Jun-30-26 | Reiterated | BTIG | Buy | $100 → $110 |
| Apr-27-26 | Reiterated | Barclays | Overweight | $104 → $110 |
| Apr-24-26 | Reiterated | Evercore ISI Group | Outperform | $94 → $93 |
| Apr-24-26 | Reiterated | Truist Securities | Hold | $89 → $90 |
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 6,513 | 6,068 | 5,440 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 1,436 | 1,327 | 1,118 | — | — | — | — | — | — | |
| Gross Profit | 5,078 | 4,741 | 4,322 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 2,201 | 2,085 | 1,789 | — | — | — | — | — | — | |
| Research and Development | 1,091 | 1,079 | 1,053 | — | — | — | — | — | — | |
| Other Operating Expense | -42 | -59 | 101 | — | — | — | — | — | — | |
| Operating Income | 1,830 | 1,636 | 1,379 | — | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 20 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -413 | -363 | 189 | — | — | — | — | — | — | |
| Net Income Before Taxes | 1,417 | 1,273 | 1,548 | — | — | — | — | — | — | |
| Income Taxes | 438 | 217 | 152 | — | — | — | — | — | — | |
| Consolidated Net Income | 1,005 | 1,074 | 4,175 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 978 | 1,056 | 1,396 | — | — | — | — | — | — | |
| Net Income | 1,005 | 1,074 | 4,175 | — | — | — | — | — | — | |
| EPS (Recurring) | 1.74 | 1.84 | 6.98 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 1.74 | 1.84 | 6.98 | — | — | — | — | — | — | |
| EPS (Diluted) | 1.74 | 1.83 | 6.97 | — | — | — | — | — | — | |
| EBITDA | 1,583 | 1,430 | 1,723 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 51.19 | 46.58 | 10.62 | — | — | — | — | — | — | |
| Price To Sales Ratio | 7.88 | 8.22 | 8.14 | — | — | — | — | — | — | |
| Gross Margin | 77.97 | 78.13 | 79.45 | — | — | — | — | — | — | |
| Operating Margin | 28.10 | 26.96 | 25.35 | — | — | — | — | — | — | |
| Net Margin | 15.43 | 17.70 | 76.75 | — | — | — | — | — | — | |
| Shares Outstanding | 576 | 585 | 598 | — | — | — | — | — | — | |
| Market Capitalization | 51,304 | 49,871 | 44,270 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Lippis Daniel J. | CVP, TAVR | Oct 08 '26 | Sale | 85.65 | 619 | 53,017 | 40,034 | Oct 08 |
| Lippis Daniel J. | CVP, TAVR | Oct 08 '26 | Option Exercise | 72.68 | 619 | 44,989 | 40,653 | Oct 08 |
| Lippis Daniel J. | CVP, TAVR | Sep 11 '26 | Sale | 87.51 | 619 | 54,169 | 40,034 | Sep 11 |
| Lippis Daniel J. | CVP, TAVR | Sep 11 '26 | Option Exercise | 72.68 | 619 | 44,989 | 40,653 | Sep 11 |
| Dahl Andrew M. | SVP, Corporate Controller | Aug 31 '26 | Sale | 91.06 | 544 | 49,534 | 14,868 | Aug 31 |
| Bruls Annette | CVP, EMEACLA | Aug 28 '26 | Sale | 89.98 | 2,644 | 237,907 | 17,984 | Aug 28 |
| Chopra Daveen | CVP, TMTT, Surgical & IHFM | Aug 26 '26 | Sale | 91.02 | 31,800 | 2,894,440 | 44,324 | Aug 26 |
| Chopra Daveen | CVP, TMTT, Surgical & IHFM | Aug 26 '26 | Option Exercise | 72.68 | 31,800 | 2,311,224 | 76,124 | Aug 26 |
| Markowitz Wayne | CVP, JAPAC | Aug 26 '26 | Sale | 91.47 | 1,240 | 113,417 | 20,294 | Aug 26 |
| Lippis Daniel J. | CVP, TAVR | Aug 11 '26 | Sale | 92.03 | 619 | 56,967 | 40,034 | Aug 11 |
| Lippis Daniel J. | CVP, TAVR | Aug 11 '26 | Option Exercise | 72.68 | 619 | 44,989 | 40,653 | Aug 11 |
| Markowitz Wayne | CVP, JAPAC | Jul 30 '26 | Sale | 86.03 | 146 | 12,588 | 21,534 | Jul 30 |
| Markowitz Wayne | CVP, JAPAC | Jul 28 '26 | Option Exercise | 74.02 | 9,628 | 712,665 | 31,308 | Jul 28 |
| Markowitz Wayne | CVP, JAPAC | Jul 28 '26 | Sale | 85.06 | 9,628 | 818,958 | 21,680 | Jul 28 |
| Zovighian Bernard J | CEO | Jul 27 '26 | Sale | 83.93 | 2,921 | 245,134 | 8,916 | Jul 27 |